Terminology
===========

The terms sex and gender refer to biological and psychosocial, respectively, origins of differences between women and men. For the purpose of this review these terms will be used interchangeable to describe any difference observed between men and women as it may impact on aspects of experimental medicine and clinical therapeutics, similar to [@B46].

The debate of the terms placebo effect and placebo response have also filled many pages, but will be ignored here for matters of simplicity. Both terms describe the results of a manipulation of treatment by providing an inert drug (in randomized controlled trials, RCT) or manipulating an experimental intervention, either for a whole group or for an individual. It has to be kept in mind, however, that some of these results of the RCT/experiment may be due to factors others than the placebo effect, specifically response biases, the Hawthorn effect, regression to the mean, spontaneous variation of symptoms, and other influences, that need to be controlled for, if at all possible ([@B37]; [@B99]). The same ignorance is applied to the differential use of terms nocebo effects and nocebo response, for which the same limitations are valid ([@B13]).

The Short History of Placebo Research
=====================================

Historically, the term "placebo" referred only to the use of inert, pill-like medicines for control of unspecific (not drug-associated) effects in RCT ([@B59]), and for the -- occasional -- use of similar remedies in everyday-medicine ([@B43]). It was later extended to include other and specifically non-medicinal therapies into the arena of evidence-based medicines. Placebo-controlled trials in surgery and other "instrumental" and manual therapies (acupuncture, stimulation techniques such as TENS, TMS, physical therapies, and alike) ([@B33]) often use the term "sham" instead, to denote that the provision of placebos in not "inert" any longer: sham surgery for instance can be associated with significant violating of the body's integrity. The application of the concept of placebos for psychotherapy and therapies alike has received very little and rather late attention and raises substantial controversy nowadays ([@B15]) over the question whether psychotherapy is to a large extent only placebo therapy ([@B49]), or whether the placebo concept should not be applied at all to psychotherapy ([@B63]).

The term "nocebo" has a much younger tradition. It was initially describing side effects (adverse events, AE) reported in RCT in the placebo arm of studies, where these AE can only occur as the consequence of mis-attributing symptoms toward the ingested (pill) placebo, or as the consequence of having read and signed AE patient information ([@B13]). Nocebo effects follow very much the rules for placebo effects both in clinical studies and in experimental settings, as we will describe below, but we will not discuss in more detail the psychobiological and neurophysiological mechanisms behind placebo and nocebo effects -- these have been extensively reported by us and others in many reviews in recent years (see for instance [@B36], [@B37]; [@B31]; [@B99]).

According to [@B46], female patients are traditionally underrepresented in clinical studies, for different reasons not to elucidate here (e.g., [@B89]). On the other hand specifically in the area on pain, sex differences are well established, both for clinical and for experimental setting ([@B83]), but also have been found to be variable with sexual orientation and identity ([@B114]). In the following sections we will review advances in research over the last decade, with respect to pain and placebo analgesia.

Sex-Effects on the Placebo Effect in RCT
========================================

While age has been shown to consistently affect placebo response rates in a number of clinical conditions investigated during RCT, sex of the patients has rarely been reported to contribute to it. Before 2010, there are only a few papers reporting stronger placebo analgesic responses in male patients ([@B12]; [@B44]). Others failed to find sex difference in placebo analgesia, e.g., with tooth extraction ([@B7]), transcutaneous electrical nerve stimulation ([@B93]), and an experimental pain test ([@B81]) In a benzodiazepine withdrawal study, female patients had higher placebo responses than males ([@B98]). However, sex differences in individual studies (e.g., [@B60]) for the irritable bowel syndrome), clinical or experimental, cannot provide sufficient evidence for or reject the assumption of sex differences existing.

In a 2013 systematic review ([@B116]) of meta-analyses and systematic review of RCT across most medical subspecialties, based on our JIPS literature database ([@B38]), we identified only three out of 75 meta-analyses that reported higher placebo response rates in female patients than in males, and in neurological and psychiatric diseases only, namely restless leg syndrome ([@B82]), bipolar mania ([@B124]), and schizophrenia ([@B74]). This however, remained not without contradiction by other meta-analyses of the same clinical conditions ([@B122]; [@B48]; [@B23]), and with analyses of similar size (see [Table 1](#T1){ref-type="table"}).

###### 

Placebo effects in meta-analyses of randomized controlled trials in selected psychiatric and neurological diseases, with respect to sex influences.

  Reference   Disease                No S    Response   Sex
  ----------- ---------------------- ------- ---------- --------
  [@B82]      RLS                    32      Pla        F \> M
  [@B74]      Schizophrenia          27      Pla        F \> M
  [@B124]     Bipolar mania          38      Pla        F \> M
  [@B122]     Schizophrenia          32      Pla        F = M
  [@B23]      Schizophrenia          31      Pla        F = M
  [@B90]      Schizophrenia          3ˆ\*    Pla        F = M
  [@B2]       Psychosis              50      Pla        F = M
  [@B62]      Autism, children       1ˆ\*    Pla        F = M
  [@B25]      OCD, anxiety           40      Pla        F = M
  [@B78]      ADHD children          10      Pla        F = M
  [@B115]     ADHD                   2ˆ\*    Pla        F = M
  [@B20]      ADHD adults            2ˆ\*    Pla        F = M
  [@B16]      BED                    10ˆ\*   Pla        F = M
  [@B18]      Depression             1ˆ\*    Pla        F = M
  [@B41]      Depression             4       Pla        F = M
  [@B105]     GAD, MDD               12      Pla        F = M
  [@B17]      Depression, children   12      Pla        F = M
  [@B19]      Depression             41      Pla        F = M
  [@B55]      Depression             1ˆ\*    Pla        F = M

In further 8 meta-analyses with 287 studies with various gastrointestinal disorders, no gender differences was found, and neither in 3 other meta-analyses 64 studies in different with medical conditions (from

Weimer et al., 2015

; for references not in our listing, we refer to this paper). No S, Number of RCT included; Response, Placebo (Pla), nocebo (Noc); Sex, M = Males, F = Females; RSL, Rest leg syndrome; MDD, Major Depression Disorder; OCD, Obsessive compulsory disease; ADHD, Attention-deficit hyperactivity disorder; BED, Binge eating disorder; GAD, General anxiety disorder.

∗

indicates availability of individualized data.

This is surprising, given that these 75 analyses -- with more than 1,500 RCT included, in more than 40 different diseases and with more than 150,000 patients -- covered neurological diseases (Parkinson's disease, restless leg syndrome, epilepsy), pain syndromes (migraine, neuropathic pain, fibromyalgia), psychiatric diseases (depression, schizophrenia, mania, psychosis, attention-deficit hyperactivity disorder, addiction), gastrointestinal disorders (visceral pain syndromes, inflammatory bowel diseases), and other disorders (asthma, overactive bladder, hypertension, allergy, chronic fatigue, sleep problems).

Adding a few more meta-analyses and conditions published since 2015 ([@B113]; [@B24]; [@B22]; [@B57]; [@B91]; [@B123]) did not reveal additional evidence for higher placebo response in either sex in any of the diseases. In consequence of this rather clear result, we are forced to conclude that in RCT in the direction and size of the placebo response is not related to the sex of the patients ([@B116]).

Sex Effects on the Nocebo Response in RCT
=========================================

The number of all papers including the term "nocebo" in our database is 431, of which only 12 (2.7%) refer to sex or gender -- implying that in the discussion of the nocebo effects much less attention is paid to sex differences. The database contains 18 meta-analyses on nocebo effects in RCT, covering more than 500 RCT with more than 25,000 patients, but excluding meta-analyses with children and adolescents, papers comparing two or more treatment modes for one condition, or with one treatment mode for more than one disease, and all experimental studies. All of these are in relation to neurological and psychiatric disorders (see [Table 2](#T2){ref-type="table"}).

###### 

Nocebo effects (adverse events) in meta-analyses of randomized controlled trials, with respect to sex influences.

  Reference   Disease            No S   Response   Sex
  ----------- ------------------ ------ ---------- --------
  [@B76]      Depression         23     Noc        F \> M
  [@B125]     Alzheimer          20     Noc        F \> M
  [@B30]      Bipolar disorder   9      Noc        F = M
  [@B53]      Fibromyalgia       18     Noc        F = M
  [@B77]      Fibromyalgia       16     Noc        F = M
  [@B29]      Major depression   20     Noc        F = M
  [@B84]      MS: DMT            55     Noc        F = M
  [@B84]      MS: ST             44     Noc        F = M
  [@B85]      Neuropathic pain   12     Noc        M \> F

No S, Number of RCT included; Response, Placebo (Pla), nocebo (Noc); Sex, M = Males, F = Females; MDD, Major Depression Disorder; CIDP, Chronic inflammatory demyelinating polyneuropathy; MS, Multiple Sclerosis; ST, Symptomatic treatment; DMT, Disease modifying treatment.

As with the placebo effect, in only three papers an association of sex and the report AE and study termination due to AE was noted: in two meta-analysis the nocebo effect was higher in women ([@B125]; [@B76]), in one it was higher in men ([@B85]). This leaves us with a similar conclusion as above, that in RCT the direction and size of the nocebo response may not be related to the sex of the patients. It neither seems to be related to age of the patients, as two analyses showed higher AE reports in younger patients ([@B77]; [@B30]), whereas another two noted higher responses in the elderly ([@B84]; [@B125]). Unfortunately however, most studies neither reported sex nor age as determining factors of the nocebo effect in RCT, either because it was not possible due to small numbers for meta-regressions, or it was not of interest to the authors.

Sex Differences in Experimental Placebo and Nocebo Studies
==========================================================

The situation is entirely different when placebo experiments are planned to evaluate the mechanisms behind the placebo/nocebo effects seen in RCT. Here recruitment of patients or volunteers can be planned based on a balance sex distribution, and eventually even matched for other social and biological variables, e.g., age, BMI, status etc., depending on the underlying hypotheses. Unfortunately, sex-balanced studies have one disadvantage that is often either ignored or has led to dismissal of female test persons altogether, that is the need for assessment and adjustment of female participants according to their menstrual cycle, e.g., with pain studies ([@B56]). In animal work, not only in placebo research, this has vastly abandoned including female animals at all in many studies ([@B28]). Surprisingly, even in experiments with patients the sex of patients is sometimes not reported (e.g., [@B88]).

A recent systematic review ([@B112]) identified 18 experiments in 17 papers (among more than 500 experiments, according to our JIPS database) reported in healthy volunteers in which sex as a contributing factor was either investigated purposely, or occurred incidentally with the data evaluation. To these 18 experiments we added 9 further experiments in healthy volunteers and 2 in different patient groups ([@B72]; [@B103]).

Experimental Placebo Studies
============================

A total of 18 experiments were performed on placebo responses in healthy volunteers ([Table 3](#T3){ref-type="table"}), nearly an equal part showed either stronger responses in males (*N* = 7) and in females (*N* = 6), and 5 showed no sex differences, leaving the question unanswered. Of the three experimental studies in patients, two showed stronger placebo responses in females while one was inconclusive.

###### 

Placebo experiments reporting sex in healthy volunteers either by verbal induction or conditioning of the response (data in part from [@B112], supplemented by further studies).

                                                      Inter-   
  --------- ---------- -------------- --------------- -------- --------
  [@B4]     63 (22)    Verbal         Pain            Pla      M \> F
  [@B45]    84 (47)    Verbal         Pain            Pla      M \> F
  [@B3]     33 (17)    Verbal         Pain            Pla      M \> F
  [@B14]    23 (7)     Verbal         Pain            Pla      M \> F
  [@B21]    20 (10)    Verbal         Pain            Pla      M \> F
  [@B1]     41 (25)    Verbal         Distress        Pla      M \> F
  [@B80]    40 (20)    Verbal         Cognition       Pla      M \> F
  [@B69]    36 (18)    Verbal         Visceral pain   Pla      F = M
  [@B94]    60 (30)    Verbal         Visceral pain   Pla      F = M
  [@B110]   30 (15)    Verbal         Visceral pain   Pla      F = M
  [@B119]   64 (32)    Verbal         Nausea          Pla      F = M
  [@B54]    32 (16)    Conditioning   Nausea          Pla      F = M
  [@B70]    49 (23)    Verbal         Pain            Pla      F \> M
  [@B27]    109 (54)   Verbal         Pain            Pla      F \> M
  [@B51]    24 (12)    Verbal         Dop response    Pla      F \> M
  [@B65]    24 (12)    Conditioning   Nausea          Pla      F \> M
  [@B106]   24 (12)    Conditioning   Nausea          Pla      F \> M
  [@B117]   64 (32)    Verbal         Rot.tolerance   Pla      F \> M

No (Fem), Total number of volunteers included (number of females); Intervention, Placebo (Pla), nocebo (Noc); Sex, M = males, F = Females.

It should be noted, however, that 12 of the 18 studies on this group are from three laboratories only: 4 from the Flaten lab in Tromsö, Norway, 3 from the Elsenbruch lab in Essen, Germany and 5 from our Düsseldorf/Tübingen labs, the remaining six are from six different labs around the world, indicating that except in these three labs, sex effects were probably accidental finding but not the focus of research. In the three laboratories providing more than one study, one group showed a male predominance, one a female predominance, and one found consistently no sex differences. It seems from the distribution in [Table 3](#T3){ref-type="table"} that there is a trend for placebo analgesia to be more effective in males, while with experimentally induced nausea females report higher placebo responses. Whether this is due to a laboratory-specific bias or specific to the clinical condition (pain or visceral pain versus nausea, for instance), or to different methods of placebo induction (verbal instruction versus conditioning), cannot be answered due to the small number of studies.

It is noteworthy though that placebo conditioning experiments have never worked for visceral pain (Sigrid Elsenbruch, personal communication); none is reported in the literature so far, despite own and other's attempts. Taking visceral pain out of the equation, it appears that verbal induction of analgesia works better in men than in women.

Important to note also is the fact that the [@B27] study used oxytocin for support the placebo effect, which is known to work specifically well in females, and may explain the paradoxical finding -- compared to all other placebo analgesia studies that reported higher responses in males. The [@B70] study was performed in children, so that data are not easily transferable to adults ([@B117]).

Experimental Nocebo Studies
===========================

[Table 4](#T4){ref-type="table"} lists the 8 experiments performed to induce a nocebo reaction in healthy volunteers; here the distribution seems cleared: Five of the eight studies, and in addition the only patient study reports higher nocebo responses in females than in males, and only 1 male predominance; two remain inconclusive.

###### 

Nocebo experiments reporting sex in healthy volunteers either by verbal induction or conditioning of the response (data in part from [@B112], supplemented by further studies).

  Reference    No (Fem)   Method         Condition       Condition   Sex
  ------------ ---------- -------------- --------------- ----------- --------
  [@B109]      84 (42)    Conditioning   Pain            Noc         F \> M
  [@B6]        111 (76)   Verbal         Pain            Noc         F \> M
  [@B64] (1)   48 (24)    Conditioning   Nausea          Noc         F \> M
  [@B42]       82 (51)    Conditioning   AE              Noc         F \> M
  [@B73]       86 (51)    Conditioning   AE              Noc         F \> M
  [@B32]       60 (30)    Verbal         Visceral pain   Noc         F = M
  [@B108]      100 (50)   Verbal         Itch            Noc         F = M
  [@B64] (2)   48 (24)    Verbal         Nausea          Noc         M \> F

No (Fem), Total number of volunteers included (number of females); Intervention, Placebo (Pla), nocebo (Noc); Sex, M = males, F = Females; AE, Adverse events.

It is noteworthy that among the six with stronger responses in females, four are conditioning studies, as are two of the placebo studies (see [Table 3](#T3){ref-type="table"}). This underlines our assumption that conditioning may work specifically well in females. When we combine the experimental placebo and the nocebo studies in healthy volunteers and compute a chi-square distribution for conditioning versus expectancy with female predominance versus female non-dominance (F = M and M \> F), it yields significance (Fisher's Exact test, *p* = 0.06, one-sided).

Behavioral Versus Physiological Responses
=========================================

Of specific note is that none of the four studies on visceral placebo analgesia ever produced sex differences at the behavioral (pain report) level, but one showed sex-dependent brain correlates of a placebo intervention despite equal subjective pain reports ([@B110]): Women exhibiting stronger responses in some brain regions (insular, prefrontal cortex) in anticipation of pain, but lower downregulation of activation in the same areas during the pain, in contrast to men; this may be indicative of the known higher pain sensitivity of females. An early PET study had demonstrated that females when exposed to placebo show significantly greater brain activation in the prefrontal cortex, as compared to the males ([@B86]). Further imaging studies showed that the (blinded) application of i.v. glucose induced dopamine and increased glucose binding in the striatum in men but not in women ([@B51]) and differentially affected blood pressure between sexes ([@B52]), underlining a similar mechanisms at the CNS level than the Theysohn et al. study. Sex differences have also been shown to exists for the opioid system ([@B79]), further supporting and explaining these differential effects on the background of approved involvement of the opioid ([@B97]) and dopamine system ([@B100], [@B101]) in placebo analgesia.

Other neuro-endocrine mediators have been nominated to the placebo response, among the first were NO ([@B104]; [@B47]), oxytocin ([@B39]), the endocannabinoid system ([@B9]), and CCK ([@B10]). While for the first (NO), an empirical prove has never been presented, the involvement and OXT has been shown ([@B61]; [@B27]; [@B111]), though not without contradictory data: While OXT worked in enhancing placebo analgesia, especially in women ([@B27]; [@B111]), it did not in dermal itch ([@B102]). Its greater action in women supports the behavioral finding of smaller effects in women in pain challenges, as compared to men: mere verbal suggestion of beneficial effects of presumed analgesics (in fact, placebos) is not sufficient to induce analgesia in women, but requires additional trust, mediated by OXT.

For CCK the involvement in nocebo hyperalgesia has only shown in one study so far ([@B10]), and for the endocannabinoid system, supporting evidence has been shown by [@B87]. Specifically for placebo and nocebo effects of hypobaric pressure (high altitude) sickness symptoms, the involvement of prostaglandins has been shown ([@B11]), but neither of these neuroendocrine mediator produced differential effects between the men and women.

Sex Effects on Experimenter -- Volunteers Interactions
======================================================

In a sham-acupuncture trial with one male and one female therapist, the female acupuncturist induced greater trust than the male in having received true acupuncture ([@B120]). In the re-evaluation of a RCT in 120 IBS patients, the female physician produced greater symptom improvements in the drug and the placebo arm of the trial than her two male colleagues, and more female than male patients responded to placebo ([@B40]). Both studies can point toward the potential role of sex of doctors in the placebo responses, but cannot prove it.

In an experimental pain study by [@B58] significant interaction of the sex of male and female experimenter (*N* = 4 each) and sex of male and female volunteers (*N* = 80 each) on pain tolerance (cold pressor test) indicated that subjects tolerated pain longer when investigated by an experimenter of opposite sex. A significant main effect was found for sex of the experimenter: higher pain intensities and higher pain tolerance were found with female experimenters.

The first experiment in a placebo research setting ([@B45]) noted higher placebo analgesia in males than in females following verbal manipulation of expectancies -- in this experiment they used five female nurses as experimenters. To further explore sex differences on pain perception, they included experimenters of both sexes (*n* = 3 each) in another experiment ([@B5]) and found significant interaction between both factors, in that female experimenters produced higher placebo analgesia in male volunteers than in females, while male experimenters did not produce similar responses, neither with male nor with female participants. This was not reflected in physiological data (heart rate), indicating -- so the authors -- the sex effect seen is probably due to psychosocial factors. In a third placebo analgesia experiment, this time with 8 experimenters (4 females), and with 64 volunteers (32 females), equally distributed in a balanced fashion, the dominant male response to female experimenters was not replicated. Instead significant sex (experimenter) × sex (volunteers) with a larger placebo analgesic response in males reporting to male experimenters, compared with male subjects reporting to female experimenters. With respect to pain reports (but not to placebo analgesia) the influence of experimenter sex persisted, however, male participants reported lower pain to female experimenters compared with the male experimenters in line with previous studies, as is a significant main effect of experimenter sex, with lower pain reports to female experimenters than to male experimenters.

Further evidence for a sex-by-sex interaction comes for two other placebo experiments, however, except [@B45], neither study has varied systematically the number and sex of the experimenters, and it may well be that the effects seen are therefore not sex- but personality-linked. [@B108] noted no sex difference in the placebo response for itch, but a difference between the one male and female investigators, with respect to the exaggerated verbal suggestion and the respective control conditions, with the female experimenter producing higher flares size in the histamine condition. In a nausea study by [@B119] that provided verbal information of the anti-emetic effect of ginger (placebo), men who received placebo responded stronger to placebo information when provided by the male experimenter, and to ginger information when provided by the female experimenter; such effect was not seen in females. One explanation provided by the authors is that women's behavior is stronger connected to their symptoms (and to information provided) than men's behavior.

Why Appear Pain and Nausea Prone to (Opposite) Sex Differences in Placebo/Nocebo Response?
==========================================================================================

Placebo and nocebo effects, as has been shown by many experimental investigations, can reliably be elicited in healthy volunteers, with many experimental paradigms, verbally induced or conditioned, but specifically with pain and nausea. At the same time, only pain and nausea have been shown to reliably be effected by sex, and two opposite conclusions can be drawn from the above discussed data:

1.  Despite higher sensitivity toward pain in females, placebo analgesia is easiest to elicit verbally in males.

2.  Conditioning is specifically effective to elicit nocebo effects, and works specifically well in females and with nausea.

For both conclusions, a rational concept is needed, despite the fact that they are based on only a few experiments from only a few placebo research groups, not necessarily interested in sex and gender differences *per se*.

For one, the above ([Tables 3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}) displayed distribution of research paradigms may be biased by an arbitrary or rational selection processes: Investigating placebo analgesia (instead of placebo responses in other areas of medicine) is determined -- among others -- by the simplicity of testing pain under laboratory conditions through a variety of techniques, that all (or many) also allow exportation into brain scanners and other advanced research technology. As we have elucidated before ([@B38]), our own decision to focus on nausea and a rotation paradigm was made before this was labeled placebo research (in 2004), as was our interest in sex differences, e.g., of nausea susceptibility ([@B107]; [@B68]).

Both pain and nausea were among the earliest clinical conditions that gain interest for their strong placebo responsiveness, as early reports from [@B8] and [@B121] indicate. At the same time, pain as well as nausea are among the most frequent symptoms reported in medicine, be it in clinical practice as subjective symptom in many somatic and functional diseases ([@B34], [@B35]), or as adverse events or patient reported outcomes in RCT of drugs and other interventions, also in the placebo arms of trials ([@B92]). At the same time, both symptoms lack a biological correlate (biomarker) that can be used reliably to measure it, so that medicine is still relying on subjective assessment of its nature (threshold, tolerance, intensity) ([@B118]; [@B96]).

Both symptoms are not *per se* diseases by their own, but rather indicative of an underlying process that requires medical attention and explanation, and only as a chronic condition (without such a process) become markers of a disease, as chronic pain or recurrent nausea and vomiting. Nausea has been called an maladaptation symptom, e.g., in the context of motion sickness ([@B71]). For women, especially nausea has an additional health relevance not apparent for men: Nausea may be indicative of pregnancy at an early stage, and may serve as a biological warning signal in the interest of the safety of the unborn life, that has overcome from evolution.

The apparent difference between men and women with regards nausea on the one hand, and to verbally induced or conditioned responses on the other hand is best illustrated by the [@B64] experiment where we showed that women respond to conditioning of nausea symptoms much better than men, while men were more susceptible toward verbally induced symptom provocation. The obvious interpretation of these differences is that for women, learning mechanisms dominate -- and previously learned content remains relevant -, while in men, an acutely provided information is of higher relevance than past experiences. This may also explain the higher susceptibility of men for verbally induced placebo analgesia, despite their lower overall pain sensitivity.

Three more experiments from our pre-placebo research tradition may further illustrate the importance of sex for nausea experience: In a study using a circular-vection drum to induce nausea ([@B66]), we found that women responded stronger to the stimulus while sitting, while in men, the lying position was much more aversive. Significant differences between sexes were also found for habituation to repetitive rotation exposure: both endocrine and inflammatory markers habituated differently between men and women with multiple (five) rotations on the same day: increases in men and decreases in women in the first session versus increases in men and in women in the last session ([@B95]). With rotations repeated over (five) consecutive days ([@B75]), males responded stronger on day 1 and reduced responses on days 2 and 3, while women responded stronger on day 3, as compared to days 1 and 2. For days 4 and 5, these trends reversed, again differentially between sexes.

All these data has led us to believe that both psychological and biological factors contribute to nausea reports in these experimental situations and interaction in rather complex ways, and presumably involving other factors that our experiments did not completely control for ([@B65], [@B67]).

The Apparent Discrepancy Between RCT and Experiments Requires an Explanation
============================================================================

In 2012, [@B46] stated that the available data are too preliminary in order to reach to a definitive conclusion, but that a sex effect on placebo responses is conceivable. In 2013, [@B116] found that sex effects on placebo responses in RCT across medicine and its subspecialties are not visible and can therefore be ignored. A few years later the evidence has substantially strengthened for sex effects in experimental work on placebo and nocebo effects, as we show above, but still remains poor for clinical RCT data. This apparent discrepancy between RCT and experimental data also needs an explanation.

The best explanation that we can provide today is referring to the different nature of experiments on the one hand and RCT on the other. In a well-planned experiment, the separation of expectancy manipulation and learning/conditioning -- as the two main underlying mechanisms of the placebo response -- can be achieved, and the relative contribution of either can be explored. For instance, this allowed [@B26] and others, to directly compare the relative potency of a novel learning mechanisms for placebo analgesia (by social observation) to the other two (expectation and conditioning).

In a randomized placebo-controlled trial, in contrast, the amount and degree of factors referring to patients' learning (medical history, previous therapies and their success and/or failure, duration of knowing the treating doctor, etc.) and to expectancies delivered and associated with the treatment (informed consent and AE reports, symptom diaries, number and intensity of doctor-patient contacts etc.) is neither known nor balanced, and may vary from patient to patient as well, e.g., in relation to his/her social environment and the "placebo by proxy" influences ([@B50]). Under these circumstances it is conceivable that any existing differences in placebo responsiveness between the sexes are averaged out in RCT, and result in equally sized placebo effects in men and women, as we have seen.
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